Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised…

By R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez and 47 more. The Lancet Oncology, 2012

5,252 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b925e8cfc1a2df68d3c4af1a5af416aa9a16ad06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Nikolaus Schultz
2. Charles Swanton
3. Jie Yang
4. Gregory Riely
5. C. Hudis
6. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. L. Sequist
4. Charles Swanton
5. Gregory Riely

Citations in the corpus

• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015, neutral): “Any grade 5 (24) 5 (9) 9 (10) 5 (8) 1 (5) 25 (10)”
• Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. (2015, background): “These latter numbers are not dissimilar from data available for other oncogene-driven NSCLCs treated with TKIs, such as epidermal growth factor receptor (EGFR) –mutated NSCLC treated with gefitinib or erlotinib.(32,33) In one report of EGFR-mutated NSCLC, the cumulative incidence of brain metastases”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “5 mth NS 15% less severe adverse reactions 4 [76]”
• Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015, neutral): “Decreased appetite 19 (15) 1 (3) 6 (32) 4 (24) 3 (19) 3 (9) 2 (33) 18 (20)”